Dow Rises More Than 200 Points as Investor Confidence Grows, Yet Fear & Greed Index Stays in 'Extreme Fear' Territory
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 06 2025
0mins
Source: Benzinga
Market Sentiment: The CNN Money Fear and Greed index showed a slight easing in fear levels but remained in the "Extreme Fear" zone at a reading of 24.1, compared to 21.5 previously.
Stock Performance: U.S. stocks rose on Wednesday, with the Dow Jones gaining over 200 points, driven by strong corporate earnings and indications that the Federal Reserve may be close to cutting interest rates.
Employment Data: The ADP National Employment Report indicated that private employers added 42,000 jobs in October, surpassing expectations and recovering from job losses in September.
Sector Movements: Most sectors of the S&P 500 closed positively, particularly communication services, consumer discretionary, and materials, while consumer staples and information technology saw declines.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 886.630
Low
950.00
Averages
1192
High
1500
Current: 886.630
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ELI LILLY - TALTZ AND ZEPBOUND ACHIEVE PRIMARY AND ALL IMPORTANT SECONDARY ENDPOINTS SHOWING STATISTICAL SUPERIORITY OVER TALTZ MONOTHERAPY AT 36 WEEKS
- Primary and Secondary Endpoints: The study focuses on the primary and all key secondary endpoints for statistical superiority related to Total Tz Monotherapy at 36 weeks.
- Statistical Superiority: The aim is to demonstrate that Total Tz Monotherapy is statistically superior in its effects compared to other treatments.
See More
Phase 3B Data Revealed at AAD Annual Meeting Demonstrates Enhanced Efficacy of Lilly's Taltz (Ixekizumab) Combined with Zepbound (Tirzepatide) for Adults with Psoriatic Arthritis and Obesity
New Data Presentation: Phase 3 data for the drugs IxeKizumab (brand name: Taltz) and Tirzepatide (brand name: Zepbound) was presented at an annual meeting.
Efficacy Results: The data demonstrated superior efficacy for adults suffering from psoriatic arthritis and obesity.
See More
Buffett Teams Up with Curry for Charity Lunch Revival
- Surging Oil Prices Impact Markets: The average price of gasoline in the U.S. has surpassed $4 per gallon for the first time since 2022, leading Wall Street to face its worst monthly and quarterly losses since 2022, prompting investors to consider the potential impact of oil prices on the stock market.
- Fed's Stabilizing Signal: Federal Reserve Chair Jerome Powell reassured investors at Harvard University that rising oil prices would not necessitate interest rate hikes, resulting in a significant drop in market expectations for future rate increases, reflecting confidence in economic stability.
- Opendoor Acquires Doma: Opendoor is acquiring parts of Doma to lower real estate transaction costs, particularly as mortgage refinancing applications decline, demonstrating the real estate market's adaptability amid rising rates due to geopolitical tensions.
- Novo Nordisk Launches Long-Term Subscriptions: Novo Nordisk has introduced multi-month subscriptions for Wegovy in an effort to compete with Eli Lilly, offering more cost-effective options that could attract additional users and enhance market share in the GLP-1 segment.
See More
Novo Nordisk Launches Wegovy Drug Subscription Program
- Subscription Program Launch: Novo Nordisk has introduced a multi-month subscription program for its Wegovy obesity drug, aiming to provide cash-paying patients with lower, predictable monthly prices, with potential annual savings of up to $1,200.
- Flexible Options: Patients can choose from three, six, or twelve-month subscriptions, with lower monthly fees for both the injection and the newly launched pill, priced at $329 for three months, $299 for six months, and $249 for twelve months for the injection.
- Competitive Market Pressure: Following the explosive uptake of Novo's pill since its U.S. launch in January, it is set to face competition from Eli Lilly's upcoming oral GLP-1, which currently holds a 60% market share in the U.S.
- Patient Support Strategy: Novo emphasizes that the subscription program not only aids patients in starting therapy but also helps them manage pricing fluctuations during treatment, aiming to enhance long-term adherence to obesity treatment.
See More
Surge in Oil Prices Triggers Market Volatility
- Oil Price Impact: The average gas price in the U.S. has surpassed $4 per gallon for the first time since 2022, indicating that the surge in crude oil prices due to the U.S.-Iran conflict is putting pressure on the market, with all three major indexes on track for their worst monthly and quarterly performance since 2022.
- Fed Policy Stability: Federal Reserve Chair Jerome Powell reassured investors at Harvard University that rising oil prices would not necessitate interest rate hikes, stating that the current rate target is 'a good place,' which led to a sharp decline in rate hike odds among traders and alleviated inflation concerns.
- Real Estate Market Consolidation: Opendoor is acquiring parts of Doma to leverage artificial intelligence in reducing real estate closing costs, particularly as mortgage refinancing applications decline, potentially enhancing its competitive edge in the market.
- Pharmaceutical Industry Competition: Novo Nordisk is launching multi-month Wegovy subscriptions to catch up with Eli Lilly in the GLP-1 market, with longer-term packages expected to save users hundreds of dollars, intensifying the competition between the two companies.
See More
Eli Lilly Acquires Centessa Pharmaceuticals to Enhance Neuroscience Portfolio
- Acquisition Overview: Eli Lilly has agreed to acquire Centessa Pharmaceuticals for $38 per share in cash, valuing the transaction at approximately $6.3 billion, with a contingent value right (CVR) potentially raising the total consideration to $47 per share, indicating strong confidence in Centessa.
- Strategic Expansion: This acquisition aims to enhance Lilly's market presence in neuroscience and sleep disorder treatments, particularly targeting experimental therapies for excessive daytime sleepiness and related neurological conditions, thereby diversifying its product pipeline.
- Positive Market Reaction: Following the announcement, Centessa Pharmaceuticals' stock surged over 46% in Tuesday's premarket trading, reflecting the market's favorable view of the deal and recognition of future growth potential.
- Potential Value Increase: The CVR could add approximately $1.5 billion in additional equity value to the transaction, further enhancing Centessa's attractiveness and indicating Lilly's optimistic outlook on its future research and development outcomes.
See More
ELI LILLY - TALTZ AND ZEPBOUND ACHIEVE PRIMARY AND ALL IMPORTANT SECONDARY ENDPOINTS SHOWING STATISTICAL SUPERIORITY OVER TALTZ MONOTHERAPY AT 36 WEEKS
- Primary and Secondary Endpoints: The study focuses on the primary and all key secondary endpoints for statistical superiority related to Total Tz Monotherapy at 36 weeks.
- Statistical Superiority: The aim is to demonstrate that Total Tz Monotherapy is statistically superior in its effects compared to other treatments.
See More
Phase 3B Data Revealed at AAD Annual Meeting Demonstrates Enhanced Efficacy of Lilly's Taltz (Ixekizumab) Combined with Zepbound (Tirzepatide) for Adults with Psoriatic Arthritis and Obesity
New Data Presentation: Phase 3 data for the drugs IxeKizumab (brand name: Taltz) and Tirzepatide (brand name: Zepbound) was presented at an annual meeting.
Efficacy Results: The data demonstrated superior efficacy for adults suffering from psoriatic arthritis and obesity.
See More
Buffett Teams Up with Curry for Charity Lunch Revival
- Surging Oil Prices Impact Markets: The average price of gasoline in the U.S. has surpassed $4 per gallon for the first time since 2022, leading Wall Street to face its worst monthly and quarterly losses since 2022, prompting investors to consider the potential impact of oil prices on the stock market.
- Fed's Stabilizing Signal: Federal Reserve Chair Jerome Powell reassured investors at Harvard University that rising oil prices would not necessitate interest rate hikes, resulting in a significant drop in market expectations for future rate increases, reflecting confidence in economic stability.
- Opendoor Acquires Doma: Opendoor is acquiring parts of Doma to lower real estate transaction costs, particularly as mortgage refinancing applications decline, demonstrating the real estate market's adaptability amid rising rates due to geopolitical tensions.
- Novo Nordisk Launches Long-Term Subscriptions: Novo Nordisk has introduced multi-month subscriptions for Wegovy in an effort to compete with Eli Lilly, offering more cost-effective options that could attract additional users and enhance market share in the GLP-1 segment.
See More
Novo Nordisk Launches Wegovy Drug Subscription Program
- Subscription Program Launch: Novo Nordisk has introduced a multi-month subscription program for its Wegovy obesity drug, aiming to provide cash-paying patients with lower, predictable monthly prices, with potential annual savings of up to $1,200.
- Flexible Options: Patients can choose from three, six, or twelve-month subscriptions, with lower monthly fees for both the injection and the newly launched pill, priced at $329 for three months, $299 for six months, and $249 for twelve months for the injection.
- Competitive Market Pressure: Following the explosive uptake of Novo's pill since its U.S. launch in January, it is set to face competition from Eli Lilly's upcoming oral GLP-1, which currently holds a 60% market share in the U.S.
- Patient Support Strategy: Novo emphasizes that the subscription program not only aids patients in starting therapy but also helps them manage pricing fluctuations during treatment, aiming to enhance long-term adherence to obesity treatment.
See More
Surge in Oil Prices Triggers Market Volatility
- Oil Price Impact: The average gas price in the U.S. has surpassed $4 per gallon for the first time since 2022, indicating that the surge in crude oil prices due to the U.S.-Iran conflict is putting pressure on the market, with all three major indexes on track for their worst monthly and quarterly performance since 2022.
- Fed Policy Stability: Federal Reserve Chair Jerome Powell reassured investors at Harvard University that rising oil prices would not necessitate interest rate hikes, stating that the current rate target is 'a good place,' which led to a sharp decline in rate hike odds among traders and alleviated inflation concerns.
- Real Estate Market Consolidation: Opendoor is acquiring parts of Doma to leverage artificial intelligence in reducing real estate closing costs, particularly as mortgage refinancing applications decline, potentially enhancing its competitive edge in the market.
- Pharmaceutical Industry Competition: Novo Nordisk is launching multi-month Wegovy subscriptions to catch up with Eli Lilly in the GLP-1 market, with longer-term packages expected to save users hundreds of dollars, intensifying the competition between the two companies.
See More
Eli Lilly Acquires Centessa Pharmaceuticals to Enhance Neuroscience Portfolio
- Acquisition Overview: Eli Lilly has agreed to acquire Centessa Pharmaceuticals for $38 per share in cash, valuing the transaction at approximately $6.3 billion, with a contingent value right (CVR) potentially raising the total consideration to $47 per share, indicating strong confidence in Centessa.
- Strategic Expansion: This acquisition aims to enhance Lilly's market presence in neuroscience and sleep disorder treatments, particularly targeting experimental therapies for excessive daytime sleepiness and related neurological conditions, thereby diversifying its product pipeline.
- Positive Market Reaction: Following the announcement, Centessa Pharmaceuticals' stock surged over 46% in Tuesday's premarket trading, reflecting the market's favorable view of the deal and recognition of future growth potential.
- Potential Value Increase: The CVR could add approximately $1.5 billion in additional equity value to the transaction, further enhancing Centessa's attractiveness and indicating Lilly's optimistic outlook on its future research and development outcomes.
See More
